Ketamine has a plasma elimination half-life of approximately 2 to 3 hours in adults. This means that roughly half of the administered drug is cleared from the bloodstream every 2 to 3 hours. After a standard 0.5 mg/kg IV infusion over 40 minutes, ketamine is essentially eliminated from the body within 10 to 12 hours. However, its antidepressant effects last far longer -- typically 3 to 14 days -- because ketamine triggers downstream neuroplastic changes that persist well after the drug itself is gone.
Metabolism and Metabolites
Ketamine is metabolized primarily in the liver by cytochrome P450 enzymes, mainly CYP2B6 and CYP3A4. The primary metabolite is norketamine, which retains roughly one-third of ketamine's potency at NMDA receptors and has its own half-life of approximately 4 to 6 hours. Norketamine is further metabolized to hydroxynorketamine (HNK) and dehydronorketamine (DHNK).
Recent research has highlighted (2R,6R)-hydroxynorketamine as a metabolite of particular interest. Zanos and colleagues (2016), publishing in Nature, found that this metabolite produces antidepressant-like effects in animal models through AMPA receptor potentiation rather than NMDA blockade. This finding suggests that ketamine's metabolites may contribute meaningfully to its therapeutic effects, extending the pharmacological activity beyond what the parent drug's short half-life would suggest.
Why Effects Outlast the Drug
The short half-life might seem contradictory to the days-long duration of antidepressant benefit. The explanation lies in ketamine's mechanism of action. During its brief time in the brain, ketamine initiates a molecular cascade -- NMDA blockade leads to glutamate release, AMPA receptor activation, BDNF signaling, and mTOR-dependent protein synthesis -- that results in the physical formation of new synaptic connections. These structural changes in the brain outlast the drug's pharmacokinetic presence by days to weeks.
The practical implications of the 2-to-3-hour half-life are important for patient management. Acute side effects such as dissociation, perceptual changes, and blood pressure elevation typically resolve within 1 to 2 hours after the infusion ends, aligning with the decline in plasma ketamine levels. Patients are generally monitored for 2 hours post-infusion and should not drive for at least 24 hours.
For detailed dosing and pharmacology information, see the Ketamine Dosing and Administration Guide.
References
- PubMed: Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics — Comprehensive pharmacokinetic review of ketamine elimination and metabolism
- PubChem: Ketamine Compound Summary — NCBI PubChem database entry for ketamine molecular pharmacology
- PubMed: GLYX-13 and Ketamine Metabolite Pharmacology — Zanos et al. (2016) on the role of hydroxynorketamine metabolites
Share